W. L. Gore & Associates received expanded FDA approval, broadening the use of its balloon-expandable stent graft, opening it up for the treatment of complex aortic aneurysms. The Viabahn VBX endoprosthesis was greenlit for use in both fenestrated and branched endovascular aortic repairs, known as FEVAR and BEVAR, where an aneurysm develops … [Read more...] about FDA approves Gore bridging stent graft in complex aortic aneurysms
W.L. Gore & Associates
Gore wins CE mark for Fortegra venous stent
W.L. Gore & Associates announced today that it received CE mark approval for its Viabahn Fortegra venous stent system. European approval comes about six months after the stent picked up FDA approval. The company labeled Viabahn Fortegra the first device for the treatment of deep venous disease in the inferior vena cava (IVC), iliac and … [Read more...] about Gore wins CE mark for Fortegra venous stent
Gore wins FDA nod for deep venous stent
W.L. Gore & Associates announced today that the FDA approved its Viabahn Fortegra venous stent, formerly known as Viafort. The company touts Viabahn Fortegra as the first device for the treatment of deep venous disease in the inferior vena cava (IVC), iliac and iliofemoral veins. It marks the latest addition to the Viabahn device family, … [Read more...] about Gore wins FDA nod for deep venous stent
W.L. Gore to acquire left atrial appendage device maker Conformal Medical
W.L. Gore & Associates announced today that it agreed to acquire left atrial appendage occlusion (LAAO) device maker Conformal Medical. The companies expect to close their deal early this year, subject to regulatory approval. Financial terms of the deal were not disclosed. Nashua, New Hampshire–based Conformal develops the CLAAS AcuForm … [Read more...] about W.L. Gore to acquire left atrial appendage device maker Conformal Medical
Conmed to exit gastroenterology product lines, transfer Gore Viabil rights to Olympus
Conmed announced that it plans to exit its gastroenterology product lines as part of a broader portfolio optimization strategy. Part of the exit includes the end of the company's distribution agreement with W.L. Gore & Associates related to the Gore Viabil biliary endoprosthesis. That deal dates back to 2006. Olympus and Gore announced in … [Read more...] about Conmed to exit gastroenterology product lines, transfer Gore Viabil rights to Olympus
Gore, Olympus ink distro deal for Viabil endoprosthesis
Olympus announced today that it entered into a distribution agreement with W.L. Gore & Associates for the Gore Viabil biliary endoprosthesis. The international agreement makes Olympus the exclusive distributor for the Viabil endoprosthesis for endoscopic placement. Olympus plans to begin commercialization over the coming months, beginning in … [Read more...] about Gore, Olympus ink distro deal for Viabil endoprosthesis
FDA approves Gore low-profile balloon-expandable endoprosthesis
W.L. Gore & Associates announced today that it received FDA approval for a lower-profile Viabahn VBX balloon-expandable endoprosthesis. FDA approval builds on the company's proven VBX stent graft for treating complex vascular disease. The company says it offers the longest balloon-expandable stent on the market (79 mm) and the widest range … [Read more...] about FDA approves Gore low-profile balloon-expandable endoprosthesis
Gore enrolls first patients in expandable stent graft trial
W.L. Gore & Associates announced today that it enrolled the first patients in a trial evaluating its Viabahn VBX stent graft. The study compares Gore’s balloon-expandable endoprosthesis to bare metal stenting for patients with complex iliac occlusive disease. It aims to inform practice guidelines around the best modalities suited for … [Read more...] about Gore enrolls first patients in expandable stent graft trial
Gore enrolls first patient in Gore ViaFort vascular stent iliofemoral study
Gore this week announced it enrolled the first U.S. patient in its pivotal study for its ViaFort vascular stent. The prospective, non-randomized, multi-center, single-arm study will have a five-year follow-up and will evaluate the investigational Gore ViaFort vascular stent for the treatment of symptomatic iliofemoral venous obstruction. It will … [Read more...] about Gore enrolls first patient in Gore ViaFort vascular stent iliofemoral study
Gore enrolls first U.S. patient in vascular stent trial
W.L. Gore & Associates announced that it enrolled the first U.S. patient in a clinical trial for its Viafort vascular stent. Gore aims to evaluate Viafort for the treatment of symptomatic inferior vena cava (IVC) obstruction with or without iliofemoral obstruction. The prospective, non-randomized, multi-center, single-arm study … [Read more...] about Gore enrolls first U.S. patient in vascular stent trial
